In cases of maternal anti-SSA antibody-induced CCHB, clinicians should evaluate myocardial attributes such as endocardial hyperplasia, as it can lead to fatal ventricular tachycardia.
Fatal VT may occur with EFE in neonatal CCHB; single case leaves open whether myocardial evaluation improves outcomes.
Newborn case of maternal anti-SSA antibody-induced congenital complete heart block (CCHB) accompanying cardiomyopathy is presented. Unexpectedly, she died of ventricular tachycardia, not bradycardia, 6 days after birth. Autopsy revealed left ventricular cardiomyopathy with endocardial fibroelastosis. Thus, when evaluating fetal cardiac performance in cases of maternal anti-SSA antibody-induced CCHB, it is necessary to pay attention to myocardial attributes such as endocardial hyperplasia.
No takes yet. Share an insight, caveat, or question.
Iida et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: